Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review (Q37316553)

19 August 2017

1 reference

title

Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review (English)

1 reference

cost-effectiveness analysis

19 August 2017

0 references

1 reference

1 reference

1 reference

M Neovius

1

1 reference

PubMed ID

18982009

19 August 2017

K Narbro

series ordinal

2

1 reference

PubMed ID

18982009

19 August 2017

language of work or name

English

0 references

publication date

4 November 2008

1 reference

International Journal of Obesity

19 August 2017

1 reference

19 August 2017

32

1 reference

19 August 2017

12

1 reference

19 August 2017

1752-1763

1 reference

https://scigraph.springernature.com/pub.10.1038/ijo.2008.189

19 August 2017

0 references

cites work

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Elevated body mass index and mortality risk in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Body-mass index and mortality in Korean men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Association between obesity status in young adulthood and disability pension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Obesity, health services use, and health care costs among members of a health maintenance organization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Cost-effectiveness of sibutramine in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Orlistat for the treatment of obesity: cost utility model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Cost-utility analysis of rimonabant in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Orlistat for the treatment of obesity: rapid review and cost-effectiveness model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Pharmacologic prevention or delay of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Estimating the effect of changes in body mass index on health state preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Cardiovascular disease risk profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Use of the health and activities limitation index as a measure of quality of life in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Coping with Type II diabetes: the patient's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Low-calorie diets and sustained weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Weight gain as a risk factor for clinical diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

An updated coronary risk profile. A statement for health professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Abdominal and total adiposity and risk of coronary heart disease in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Variations in population health status: results from a United Kingdom national questionnaire survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

Disability pension, employment and obesity status: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Rimonabant for overweight or obesity

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Long-term pharmacotherapy for obesity and overweight

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Economic evaluation of treatment with orlistat in Italian obese patients

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

A new method for testing synthetic drugs adulterated in herbal medicines based on infrared spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Long-term weight-loss maintenance: a meta-analysis of US studies

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Abdominal adiposity and coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Weight and blood pressure. Findings in hypertension screening of 1 million Americans

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.189

7 January 2021

Identifiers

DOI

10.1038/IJO.2008.189

1 reference

19 August 2017

1 reference

PubMed ID

18982009